In our experimental setup, the observed reduction of specifically bound MB with VEGFR2-targeted CEUS under anti-PD-L1/anti-CTLA-4 immunotherapy of malignant melanoma may be explained by the pathophysiological connection between VEGF and tumour immunology. The gene discussed is VEGFA; the disease is melanoma.